Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900651 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 139
- Enrollment target
NCT02900651 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 139 participants.
The verdict
NCT02900651, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.
Interventions
- DRUG MAK683
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2016-10-03 |
| Est. Completion | 2024-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02900651
The ClinicalTrials.gov registry entry for NCT02900651 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MAK683 is the first listed.
NCT02900651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02900651 about?
NCT02900651 is a clinical study titled "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies". The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL),...
What is the current status of trial NCT02900651?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 139 participants. The study started on 2016-10-03. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT02900651?
The interventions under investigation include: MAK683 (DRUG).
Who is sponsoring clinical trial NCT02900651?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.